Denver City And County, Colorado; General Obligation Jan 08

  • ID: 2035933
  • January 2008
  • Region: Colorado
  • Standard & Poors
1 of 3


  • Denver Brd of Wtr Comr
  • Denver City & Cnty
  • MORE

Standard & Poor's Ratings Services assigned its 'AA+' rating, with a stable outlook, to Denver City and County, Colo.'s series 2008 GO justice system facility bonds and supplemental interest coupons. At the same time, Standard & Poor's affirmed its 'AA+' rating on the city's outstanding GO debt, and city GO debt issued on behalf of the Denver Board of Water Commissioners. The outlook is stable. The rating reflects Denver's: Position as the center of a large and diverse metropolitan economy that serves as a regional trade and employment center; Maintenance of a large fund balance position and willingness to implement proactive midyear budget-cutting when necessary to maintain general fund unrestricted reserves at the city's minimum goal of 15% of expenditures;...

Companies mentioned in this report are:
- Denver City & Cnty
- Denver Brd of Wtr Comr

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Denver City & Cnty
- Denver Brd of Wtr Comr

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.